Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca’s (AZN) WAINZUA eplontersen has been approved in the European Union EU for ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...

The board of Assura Group (LON: AGRP) (LSE:AGR) has given the thumbs up a £1.6 billion takeover bid from KKR and Stonepeak ...

Shore Capital restated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a report released on Friday morning, Marketbeat.com reports. A number of other equities research analysts ...

Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dolsten, who served as Pfizer’s chief scientific officer and ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

AstraZeneca is withdrawing its corona vaccine Vaxzevria worldwide.

A new study has identified genetic variants in the ITSN1 gene that significantly increase the risk of developing Parkinson’s ...

Scientists have identified a rare genetic mutation in ITSN1 that increases the risk of Parkinson’s disease by up to tenfold, ...

AstraZeneca (NASDAQ:AZN) said on Friday that its gastric cancer treatment, IMFINZI, demonstrated a statistically significant ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...